Stryker Corporation (SYK)
Health Care · $106B market cap · SEC CIK 0000310764
fundamentals score out of 100
Next reports on Oct 28, 2026, after the close, with analysts expecting $3.61 in earnings per share.
The case for SYK
- Generated $4.3B of free cash flow in FY2025, 17% of revenue.
- Revenue growing 8.5% year over year.
- Earnings per share up 27.7%.
- Has compounded revenue at 11.8% a year over five years.
- Return on equity of 16%.
- Gross margin of 65% absorbs cost shocks.
The case against
- Down 27.2% over the past year.
- Near the bottom of its 52-week range, 30% below the high. Falling prices usually have a reason; find it first.
What the score is made of
Each factor is half a curve over reported figures and half a rank among the other Health Care companies (momentum is judged against fixed thresholds only), and the five are blended by weight. It describes the last filing and the current price. It is not a forecast.
| Valuewhat you pay for the earnings, sales, assets and cash | 47 |
|---|---|
| Growthhow fast revenue and earnings are moving, this year and over five | 74 |
| Profitabilityhow much of the revenue becomes profit, and how much of that is cash | 70 |
| Momentumhow the price has behaved lately | 17 |
| Stabilityhow violently it moves, what it owes and what it pays you | 62 |
- Each factor except momentum is half fixed thresholds, half rank among the 59 Health Care companies.
Key numbers
| Price / earnings | 28.5× |
|---|---|
| Price / book | 5.03× |
| Price / sales | 4.1× |
| Revenue growth (YoY) | +8.5% |
| EPS growth (YoY) | +27.7% |
| Gross margin | 65% |
| Operating margin | 21% |
| Net margin | 14% |
| Return on equity | 16% |
| Debt / equity | 0.62× |
| Current ratio | 2.16 |
| Dividend yield | 1.02% |
| Beta | 0.79 |
| 52-week range | $267.00 – $392.55 |
| Position in that range | 6% of the way up |
| 3-month return | -10.9% |
| 1-year return | -27.2% |
Five years of financials, as filed
Pulled from Stryker Corporation's XBRL filings on SEC EDGAR. Italic rows are derived from the rows above.
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | $25.1B | $22.6B | $20.5B | $18.4B | $17.1B |
| Gross profit | $16.1B | $14.4B | $13.1B | $11.6B | $11.0B |
| Operating income | $4.9B | $3.7B | $3.9B | $2.8B | $2.6B |
| Net income | $3.2B | $3.0B | $3.2B | $2.4B | $2.0B |
| Operating cash flow | $5.0B | $4.2B | $3.7B | $2.6B | $3.3B |
| Capital expenditure | $761M | $755M | $575M | $588M | $525M |
| Total assets | $47.8B | $43.0B | $39.9B | $36.9B | $34.6B |
| Total liabilities | $25.4B | $22.3B | $21.3B | $20.3B | $19.8B |
| Cash | $4.0B | $3.7B | $3.0B | $1.8B | $2.9B |
| Long-term debt | $14.9B | $12.2B | $10.9B | $11.9B | $12.5B |
| Free cash flow | $4.3B | $3.5B | $3.1B | $2.0B | $2.7B |
| Gross margin | 64.0% | 63.9% | 63.7% | 62.8% | 64.1% |
| Operating margin | 19.5% | 16.3% | 19.0% | 15.4% | 15.1% |
| Net margin | 12.9% | 13.2% | 15.4% | 12.8% | 11.7% |
| Diluted shares | 387M | 386M | 384M | 382M | 382M |
Share count is essentially flat over 4 years.
What Stryker Corporation says it does
Stryker Corporation (Stryker or the Company) is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. Our core values guide our behaviors and actions and are fundamental to how we execute our mission. Stryker was incorporated in Michigan in 1946 as the successor company to a business founded in 1941 by Dr. Homer H. Stryker, a prominent orthopaedic surgeon and inventor of several medical products. Our products are sold in approximately 61 countries through company-owned subsidiaries and branches as well as third-party dealers and distributors, and include surgical equipment and surgical navigation systems; endoscopic and communications systems;…
Risk factors SYK lists in its 10-K
- We use a variety of raw materials, components, devices and
- third-party services in our global supply chains, production
- and distribution processes; significant shortages, price
- increases or unavailability of third-party services have in the
- past increased, and could in the future increase, our
- operating costs and could require significant capital
- expenditures or adversely impact the competitive position of
- We are subject to pricing pressures as a result of cost
- containment measures in the United States and other
- countries and other factors, including changes in
- reimbursement practices and coverage policies and third-
- party payor cost containment measures
- Dollar amounts in millions except per share amounts or as otherwise specified
- We operate in a highly competitive industry in which